Tenderwize
Retour à la recherche

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical products for the medicinal combination Lamivudin/Abacavir/Dolutegravir.
  • Open House rebate agreements under § 130c(1) SGB V.
Afficher le résumé complet

This is an Open House supply arrangement by Techniker Krankenkasse for the pharmaceutical product combination Lamivudin/Abacavir/Dolutegravir (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with no individual negotiations and no exclusivity. The contract runs from 01.03.2025 to 28.02.2027 at the latest, but no contract value is provided. Participation and contract documents are only available electronically via the buyer portal, while submission is not allowed through the portal and must be made by email with qualified electronic signature or by post. The notice also states that the publication is not considered a public procurement contract under procurement law, so remedies are directed to social courts rather than procurement review bodies.

Risques

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Single lot covering Open House rebate agreements for the medicinal product combination Lamivudin/Abacavir/Dolutegravir. The scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated eligibility conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 27, 2027

Détails de la procédure

Date de publication
20 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
42947-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3